Riskpilot← Back to searchSign inGet full accessGalaxa Pharma a/s
A/SActiveCVR 41183144Indiakaj 10, 2.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20201 employees
Revenue 2025
DKK -399K
-56% vs 2024
EBITDA margin
100.0%
+56% vs 2024
Equity ratio
-14.9%
Financial strength
Net profit 2025
DKK -461K
+44% vs 2024
| Revenue | DKK -399K | -56% |
| EBITDA | DKK -399K | +56% |
| Net profit | DKK -461K | +44% |
| Total assets | DKK 1,4M | -12% |
| Equity | DKK -210K | -183% |
| Employees | 1 | — |
Legal name
Galaxa Pharma a/s
CVR number
41183144
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. februar 2020
Share capital
DKK 1.000.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør i forening med et bestyrelsesmedlem, af tre medlemmer af bestyrelsen eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive medicinalvirksomhed og hermed forbundne aktiviteter
Address
Indiakaj 10, 2.
Phone
+4527742280
Email
info@galaxapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -6 | 666 | -846 | -1.971 | -898 | -399 |
| Staff expenses | -0 | -194 | -1.602 | -13 | -2 | -0 |
| EBITDA | -6 | -200 | -2.448 | -1.959 | -900 | -399 |
| Depreciation & amort. | -0 | -0 | -113 | -113 | -113 | -4 |
| EBIT | -6 | -200 | -2.561 | -2.072 | -1.013 | -403 |
| Net financials | 0 | -2 | -143 | -77 | -71 | -35 |
| Profit before tax | -6 | -202 | -2.704 | -2.149 | -1.084 | -438 |
| Tax | -0 | -68 | -658 | -406 | -264 | 23 |
| Net profit | -6 | -134 | -2.046 | -1.743 | -820 | -461 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 500 | 3.380 | 3.074 | 2.584 | 1.598 | 1.402 |
| Equity | 494 | 360 | 814 | 572 | 252 | -210 |
| Long-term debt | 1 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 3.020 | 2.260 | 2.012 | 1.347 | 1.612 |
| Total debt | 6 | 3.020 | 2.260 | 2.012 | 1.347 | 1.612 |
EBITDA margin
-39887400.0%
This company
15.8%
Market median
-252451999% vs market
20202025
Equity ratio
-14.9%
This company
38.2%
Market median
-139% vs market
20202025
Return on equity
-46128100.0%
This company
18.4%
Market median
-250696296% vs market
20202025
Net profit margin
-46128100.0%
This company
8.1%
Market median
-569482816% vs market
20202025
Asset turnover
-0.28×
This company
1.12×
Market median
-125% vs market
20202025
Debt / equity
7.69×
This company
0.62×
Market median
-1140% vs market
20202025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2020-02-07 – 2020-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LH Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
CS MEDICA a/s | Company | 100.0% | 100.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CoLund ApS
Galaxa Pharma a/s Board members of Galaxa Pharma a/s also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lone Henriksen | Chief Executive Officer | 0 companies |
| Flemming Heegaard | Chairman | 0 companies |
| Karsten Adelmark | Board of Directors | 0 companies |
| Jørgen Flemming Ladefoged | Chairman | 0 companies |
| Simon Tønners | Board of Directors | 0 companies |
| Ib Madsen | Board of Directors | 0 companies |
| Alexandre Fevre | Board of Directors | 0 companies |
| Bo Erik Lennart Unéus | Board of Directors | 0 companies |
| Gitte Henriksen | Board of Directors | 0 companies |
| Stein Arve Løkstad | Board of Directors | 0 companies |
| Mads Verner Jørgensen | Board of Directors | 0 companies |
| Jens Jørgen Hagelskjær | Board of Directors | 0 companies |
| Jesper Herold Halle | Board of Directors | 0 companies |
| Anders Permin | Board of Directors | 0 companies |